{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=growth+hormone+treatment", "query": { "intervention": "growth hormone treatment" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 329, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=growth+hormone+treatment&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T23:41:40.958Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02513394", "title": "PALbociclib CoLlaborative Adjuvant Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Standard Adjuvant Endocrine Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5796, "start_date": "2015-08", "completion_date": "2028-12", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-02T23:41:40.958Z", "location_count": 192, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02513394" }, { "nct_id": "NCT04109066", "title": "Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel (PTX)", "type": "DRUG" }, { "name": "nivolumab placebo", "type": "OTHER" }, { "name": "anthracycline", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Endocrine Therapy", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 521, "start_date": "2019-11-18", "completion_date": "2023-12-27", "has_results": true, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-10-02T23:41:40.958Z", "location_count": 30, "location_summary": "Mobile, Alabama • Greenbrae, California • Whittier, California + 27 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Greenbrae", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04109066" }, { "nct_id": "NCT02525029", "title": "Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Graft vs Host Disease" ], "interventions": [ { "name": "Pregnyl®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "76 Years", "sex": "ALL", "summary": "Up to 76 Years" }, "enrollment_count": 53, "start_date": "2016-03", "completion_date": "2022-04", "has_results": true, "last_update_posted_date": "2023-12-14", "last_synced_at": "2026-10-02T23:41:40.958Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02525029" }, { "nct_id": "NCT06058377", "title": "Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2-Negative Breast Carcinoma", "Hormone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Genetic Testing", "type": "OTHER" }, { "name": "Mammography", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3680, "start_date": "2023-11-27", "completion_date": "2032-05-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-02T23:41:40.958Z", "location_count": 555, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 427 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06058377" }, { "nct_id": "NCT03959891", "title": "AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 77, "start_date": "2019-05-30", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-02T23:41:40.958Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03959891" }, { "nct_id": "NCT00002552", "title": "Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "perfosfamide", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "syngeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 40, "start_date": "1993-10", "completion_date": "2003-10", "has_results": false, "last_update_posted_date": "2013-04-09", "last_synced_at": "2026-10-02T23:41:40.958Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002552" }, { "nct_id": "NCT03038594", "title": "Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Burns", "Growth Hormone Treatment" ], "interventions": [ { "name": "Somatropin", "type": "DRUG" }, { "name": "0.09% Saline Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Medical Branch, Galveston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 13, "start_date": "2015-11-01", "completion_date": "2021-11-30", "has_results": false, "last_update_posted_date": "2023-02-13", "last_synced_at": "2026-10-02T23:41:40.958Z", "location_count": 1, "location_summary": "Galveston, Texas", "locations": [ { "city": "Galveston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03038594" }, { "nct_id": "NCT04095273", "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Elimusertib (BAY1895344)", "type": "DRUG" }, { "name": "Pembrolizumab (Keytruda®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2019-09-30", "completion_date": "2023-04-11", "has_results": false, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-02T23:41:40.958Z", "location_count": 8, "location_summary": "Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04095273" }, { "nct_id": "NCT00245037", "title": "Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Precancerous Condition" ], "interventions": [ { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Granulocyte colony-stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Phenytoin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 147, "start_date": "2005-06", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-09-27", "last_synced_at": "2026-10-02T23:41:40.958Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00245037" }, { "nct_id": "NCT06843967", "title": "A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Well Differentiated Liposarcoma", "Dedifferentiated Liposarcoma", "Liposarcoma", "Myxoid Liposarcoma", "Round Cell Liposarcoma", "Myxoid Pleomorphic Liposarcoma", "Pleomorphic Liposarcoma", "Unresectable Liposarcoma", "Unresectable Dedifferentiated Liposarcoma" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2025-02-19", "completion_date": "2028-08-19", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-02T23:41:40.958Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06843967" } ] }